SREBP1 Antibodies
We offer SREBP1 Antibodies for use in common research applications: ELISA, Immunocytochemistry/Immunofluorescence, Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Sandwich ELISA, Simple Western, Western Blot. Each SREBP1 Antibody is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. Our SREBP1 Antibodies can be used in a variety of model species: Bovine, Canine, Chicken, Golden Syrian Hamster, Hamster, Human, Mouse, Plant, Porcine, Rat. Use the list below to choose the SREBP1 Antibody which is most appropriate for your research; you can click on each one to view full technical details, images, references, reviews and related products. Choose from our SREBP1 polyclonal antibodies and browse our SREBP1 monoclonal antibody catalog.
Alternate Names for SREBP1 Antibodies
anti-SREBP1 antibody, anti-SREBF1 antibody, anti-BHLHD1 antibody, anti-Class D basic helix-loop-helix protein 1 antibody, anti-SREBP 1c antibody, anti-SREBP-1 antibody, anti-SREBP1bHLHd1SREBP-1c antibody, anti-sterol regulatory element binding protein-1 antibody, anti-sterol regulatory element binding transcription factor 1 antibody, anti-sterol regulatory element-binding protein 1 antibody, anti-Sterol regulatory element-binding transcription factor 1 antibody
10 Results for "srebp1" in Primary Antibodies
![Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Hepatic SREBP1c and SREBP2 protein abundance in C57BL/6 mice assigned to a high-fat (HF) or a high-fat/exercise (HF + EX) group for 8 weeks. Cytosolic and nuclear SREBP1c abundance. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/jl/2013/908048/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Western-Blot-NB600-582-img0004.jpg "Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Hepatic SREBP1c and SREBP2 protein abundance in C57BL/6 mice assigned to a high-fat (HF) or a high-fat/exercise (HF + EX) group for 8 weeks. Cytosolic and nuclear SREBP1c abundance. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/jl/2013/908048/), licensed under a CC-BY license.")
![Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Analysis of whole cell lysate from HeLa cells showing a single specific band for the expression of SREBP1 precursor protein (~120 kDa).](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Western-Blot-NB600-582-img0002.jpg)
![Simple Western: SREBP1 Antibody (2A4) [NB600-582] - Lane view shows a specific band for SREBP1 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Simple-Western-NB600-582-img0003.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: SREBP1 Antibody (2A4) [NB600-582] - KO and OE of SREBP1 influenced lipid metabolism in Bel-7402 cells. The protein level of lipid-associated genes in SREBP1-KO, SREBP1-OE, and WT Bel-7402 cells. Data were expressed as mean -/+ standard error of the mean. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. WT group, respectively.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Knockout-Validated-NB600-582-img0005.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Effect of GEN on the expression of Nrf2‐related signalling proteins in OA (660 μmol/L) & PA (330 μmol/L)‐induced HepG2 cells. GEN was added into HepG2 cells prior 1 h to stimulation of OA & PA for 18 h. A‐C, Protein expression of Nrf2, PPAR alpha , PPAR gamma in nucleus & HO‐1 in cytoplasm was detected by Western blot. (D & E) Protein expression of P‐ACC, ACC, P‐AKT, AKT, P‐AMPK alpha , AMPK alpha , P‐AMPK beta & AMPK beta was detected by Western blot. F‐H, Protein expression of PI3K, P‐mTORC, mTORC, P‐S6K, S6K, P‐S6, S6, SREBP‐1c & HMGB1 was detected by Western blot. The similar results were collected from three dependent experiments. All data were expressed by mean ± SEM (n = 5 in each group). ##P < .01 vs Control Group; *P < .05 & **P < .01 vs OA & PA Group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32293113), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-31020241534375.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - KO & OE of SREBP1 influenced lipid metabolism in Bel-7402 cells. (A) Total cellular TG content of SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (B) HPLC-MS determination of the SFAs to MUFAs ratios (palmitic acid to palmitoleic acid, 16:0 to 16:1) (stearic acid to oleic acid, 18:0 to 18:1) as well as the content of 16:0, 16:1, 18:0, & 18:1 in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (C) The transcript level of lipid-associated genes in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (D & E) The protein level of lipid-associated genes in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. Data were expressed as mean ± standard error of the mean. *P < 0.05, **P < 0.01, & ***P < 0.001 vs. WT group, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31297058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202415384185.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Construction of knockout (KO) & overexpression (OE) cell lines. (A) The sequencing results of KO positive clone cells; (B) The messenger RNA (mRNA) level of SREBP1 in wild type (WT) & OE Bel-7402 cells. Data were expressed as mean ± standard error of the mean. ***P < 0.001 vs. WT group; (C & D) The protein level of SREBP1 in WT, OE, & KO Bel-7402 cells. Data were expressed as mean ± standard error of the mean. ***P < 0.001 vs. WT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31297058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-31020241539748.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - p75NTR stimulation activated SREBP1 & SREBP2 in Huh7 hepatocyte cells.Human Huh7 cells were stimulated with 10 ng/ml pro-NGF or 50 ng/ml NGF for 16 h followed by immunoblotting using antibodies to detect the presence of cleaved/activated SREBP1 & SREBP2. a SREBP1, immunoblots & b quantification. Values are mean ± SD, n = 3. **P < 0.01 & *p < 0.05 for treated vs. control cells. c, d SREBP2. Cells were treated with 10 ng/ml pro-NGF in the absence or presence of 0.5 μM PF429242 (PF), which is a selective inhibitor of the Site 1 protease (S1P). c Immunoblots & d quantification. PF decreased the amount of processed SREBP2 in these cells; however, addition of pro-NGF increased the relative level of cleaved SREBP2. Values are mean ± SD, n = 3. *p < 0.05 for treated vs. the corresponding control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31296846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416161836.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - p75NTR stimulation activated SREBP1 & SREBP2 in Huh7 hepatocyte cells.Human Huh7 cells were stimulated with 10 ng/ml pro-NGF or 50 ng/ml NGF for 16 h followed by immunoblotting using antibodies to detect the presence of cleaved/activated SREBP1 & SREBP2. a SREBP1, immunoblots & b quantification. Values are mean ± SD, n = 3. **P < 0.01 & *p < 0.05 for treated vs. control cells. c, d SREBP2. Cells were treated with 10 ng/ml pro-NGF in the absence or presence of 0.5 μM PF429242 (PF), which is a selective inhibitor of the Site 1 protease (S1P). c Immunoblots & d quantification. PF decreased the amount of processed SREBP2 in these cells; however, addition of pro-NGF increased the relative level of cleaved SREBP2. Values are mean ± SD, n = 3. *p < 0.05 for treated vs. the corresponding control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31296846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416175210.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Effect of GEN on the protein expression of Nrf2, ACC & mTORC signalling pathways in tyloxapol‐induced mice. GEN (50, 75, 100 mg/kg) was administered to WT or Nrf2−/− mice prior 1 h to stimulation of tyloxapol (500 mg/kg) for 18 h. A‐C, Protein expression of Nrf2, PPAR alpha , PPAR gamma in nucleus & HO‐1 in cytoplasm of WT mice was detected by Western blot. (D & E) Protein expression of Nrf2, PPAR alpha & PPAR gamma in Nrf2−/− mice was detected by Western blot. F‐H, Protein expression of P‐ACC, ACC, P‐AKT, AKT, P‐AMPK alpha , AMPK alpha , P‐AMPK beta , AMPK beta in WT & Nrf2−/− mice was detected by Western blot. I‐M, Protein expression of PI3K, P‐mTORC, mTORC, P‐S6K, S6K, P‐S6, S6, SREBP‐1c & HMGB1 WT & Nrf2−/− mice was detected by Western blot. The similar results were collected from three dependent experiments. All data were expressed by mean ± SEM (n = 5 in each group). ##P < .01 vs Control group; *P < .05 & **P < .01 vs Tyloxapol group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32293113), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416171460.jpg)
![Simple Western: SREBP1 Antibody [NB100-2215] - Image shows a specific band for SREBP1 in 1 mg/mL of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Simple-Western-NB100-2215-img0007.jpg "Simple Western: SREBP1 Antibody [NB100-2215] - Image shows a specific band for SREBP1 in 1 mg/mL of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - CDC2 associates with SPDY at ERES. (A-C) 0 h GV stage oocyte labeled for CDC2 (A, green), DNA (A, blue), and SPDY (B, red). Both CDC2 and SPDY localize to the same cortical domain (C). Note that the center of this oocyte is dented (the area that contains the arrow) causing the structure to appear in the middle of the oocyte, whereas it is located in the cortex. Images are Z-projections of 2 (A-C); scale bars represent 20 um in C and 5 um in C'. Arrows indicate the region of the oocyte that is shown enlarged in the insets (B'-C'). Arrowheads denote the position of the GV. Image collected and cropped by CiteAb from the following publication (//bmcdevbiol.biomedcentral.com/articles/10.1186/1471-213X-9-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2215-img0011.jpg)
![Western Blot: SREBP1 Antibody [NB100-2215] - MiR-181a overexpression impairs and miR-181a inhibition improves glucose and lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1. 2 mM NEFA), and miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors and then treated with 1. 2 mM NEFA). It was followed with or without 100 nM insulin. Immunoblot analysis (left) and quantification (right) of SREBP-1c and PPARI+- in HepG2 cells. Image collected and cropped by Citeab from the following publication (Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-2215-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-2215] - SREBP1 antibody was tested in HeLa cells with DyLight488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Nuclear and punctate vesicle staining was observed.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2215-img0006.jpg)
![Immunohistochemistry-Paraffin: SREBP1 Antibody [NB100-2215] - nalysis of FFPE tissue section of mouse liver with SREBP1 antibody at 1:200. The antibody generated an expected cytoplasmic-nuclear immunostaining of SREBP1 protein in the hepatocytes.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunohistochemistry-Paraffin-NB100-2215-img0008.jpg)
![Western Blot: SREBP1 Antibody [NB100-2215] - Detection of SREBP1. Lane 1: human liver. Lane 2: mouse liver.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-2215-img0004.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid homeostasis in HepG2 cellsHepG2 cells were divided into 4 groups as follows: a control group, mimics group (HepG2 cells transfected with 10 nM mimics), NEFA group (treated with 1.2 mM NEFA), & miR-181a + NEFA group (transfected with 50 nM miR-181a inhibitors & then treated with 1.2 mM NEFA). B was followed with or without 100 nM insulin. (A) Immunoblot analysis (top) & quantification (bottom) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in HepG2 cells. (B) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of AKT in HepG2 cells. (C) Glucose concentration in medium. (D) The glycogen content in HepG2 cells. (E) The mRNA expression levels of G6Pase & PEPCK. (F) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha in HepG2 cells. (G) TG content in HepG2 cells. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682194.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on liver.Liver was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in liver. A2bAR KO (n = 5) vs WT (n = 7) p-value = 0.0271; A2bAR KO vs CD68-Tg (n = 6) p-value = 0.0210. B. mRNA expression of IL-6 in liver. A2bAR KO (n = 8) vs WT (n = 7) p-value = 0.0159; A2bAR KO vs CD68-Tg (n = 8) p-value = 0.0080. C. mRNA expression of IRS-2 in liver. CD68-Tg (n = 7) vs A2bAR KO (n = 8) p-value = 0.0300. D. Western blot analysis of liver; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. Levels of mature SREBP-1 (68 kDa), & IRS-2 (185 kDa), were probed by Western blot analysis, using beta -actin (43 kDa) as loading control. Quantification of Western Blot results was performed with Image J software (//rsb.info.nih.gov/ij/) with normalization to beta -actin. WT to A2bAR KO: IRS-2 p-value = 0.0092, SREBP-1 p-value = 0.0154; CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0247, SREBP-1 p-value = 0.0170. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682175.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression or SIRT1 knockdown impairs glucose & lipid metabolism in vivo(Aa & Ab) Immunoblotting analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (B) Glucose tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (C) Insulin tolerance test of mice injected with Ago-181a (n = 7) or Ago-NC (n = 7) or Ad-shRNA NC (n = 6) or Ad-shRNA SIRT1 (n = 6). (D) Representative images of PAS staining (original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ea & Eb) Immunoblotting analysis (top) & quantification (bottom) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (F) Representative images of H&E staining (left, original magnification × 20) & Oil-red staining (right, original magnification × 20) of liver sections from mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. (Ga & Gb) Immunoblotting analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in the liver of mice injected with Ago-181a or Ago-NC or Ad-shRNA NC or Ad-shRNA SIRT1. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241553209.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - MiR-181a overexpression impairs & miR-181a inhibition improves glucose & lipid metabolism in vitro(A, B, C, D & E) Hepatocytes were transfected with 10 nM miR-181a mimics or negative controls in the absence or presence of 100 nM insulin. (A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (B) The mRNA expression levels of G6Pase & PEPCK in hepatocytes. (C) Glucose concentration in medium. (D) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (E) TG content in hepatocytes. (F, G, H, I & J) Hepatocytes were transfected with 50 nM miR-181a inhibitors or negative controls in the absence or presence of 100 nM insulin. (F) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta in hepatocytes. (G) The expression levels of G6Pase & PEPCK in hepatocytes. (H) Glucose concentration in medium. (I) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha expression in hepatocytes. (J) TG content in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-310202415535169.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - Effect of restoration of macrophage A2bAR on adipose tissue.Visceral (epididymal) adipose tissue was collected from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD as described in the methods. A-C,E. Relative mRNA expression was determined using the delta delta CT method with normalization to 18s rRNA. A. mRNA expression of TNF-alpha in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0345. B. mRNA expression of IL-6 in visceral fat. A2bAR KO (n = 7) vs WT (n = 7) p-value = 0.0073; A2bAR KO vs CD68-Tg (n = 7) p-value = 0.0141. C. mRNA expression of MCP1 in visceral fat. A2bAR KO (n = 7) vs CD68-Tg (n = 9) p-value = 0.0232. D. Visceral adipose tissue from WT, A2bAR KO, & CD68-Tg mice after 16 weeks of HFD was fixed in 4% paraformaldehyde & paraffin-embedded. Sections immunostained with the macrophage marker F4/80. Representative sections for each genotype at a magnification of 200x & 400x. Arrows point to crown-like structures. E. mRNA expression of IRS-2 in visceral fat. CD68-Tg (n = 8) vs A2bAR KO (n = 8) p-value = 0.0115, WT (n = 6) vs A2bAR KO p-value = 0.0358. F. Western blot analysis of visceral fat; one representative (of 3 sets) WT, CD68-Tg & A2bAR KO group shown at 15 minutes post-insulin injection, following 16 weeks of HFD. WT to A2bAR KO: IRS-2 p-value = 0.0411, SREBP-1 p-value = 0.0103. CD68-Tg to A2bAR KO: IRS-2 p-value = 0.0305, SREBP-1 p-value = 0.0459. Data are averages ± SD. *Student two-tail t-test assuming equal variance was found significant only when p-value <0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24892847), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-31020241682189.jpg)
![Western Blot: SREBP1 Antibody - BSA Free [NB100-2215] - SIRT1 knockdown impairs & SIRT1 overexpression improves glucose & lipid metabolism in hepatocytes(A) Immunoblot analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, Akt & GSK3 beta protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA with or without 100 nM insulin. (B) Immunoblot analysis (left) & quantification (right) of SREBP-1c & PPAR alpha protein levels in hepatocytes. Hepatocytes were transfected with SIRT1 siRNA. (C) Immunoblot analysis (left) & quantification (right) of SIRT1, PGC-1 alpha & acetylated PGC-1 alpha in hepatocytes. Hepatocytes were infected with Ad-SIRT1. (D) Immunoblotting analysis (left) & quantification (right) of insulin-stimulated phosphorylation of IR, AKT & GSK3 beta in hepatocytes. Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1 with or without 100 nM insulin. (E, F & G) Hepatocytes were treated with 1.2 mM NEFA or 1.2 mM NEFA & Ad-SIRT1. (E) Glucose concentration in medium. (F) Immunoblot analysis (top) & quantification (bottom) of SREBP-1c & PPAR alpha in hepatocytes. (G) TG contents in hepatocytes. *P < 0.05, **P < 0.01. All experiments were repeated at least three times & representative results are shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29207650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2215_rabbit-polyclonal-srebp1-antibody-310202415541953.jpg)
![Western Blot: SREBP1 Antibody [NB100-74542] - Analysis of 25 ug of mouse liver (lane 1), rat liver (lane 2) and HepG2 (lane 3) cell lysates onto an SDS polyacrylamide gel.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Western-Blot-NB100-74542-img0008.jpg "Western Blot: SREBP1 Antibody [NB100-74542] - Analysis of 25 ug of mouse liver (lane 1), rat liver (lane 2) and HepG2 (lane 3) cell lysates onto an SDS polyacrylamide gel.")
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-74542] - Analysis of SREBP1 (green) showing staining in the cytoplasm of C2C12 cells (right) compared to a negative control without primary antibody (left).](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74542-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-74542] - Analysis of SREBP1 (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left).](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74542-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NB100-74542] - Analysis of SREBP1 (green) showing staining in the cytoplasm of HepG2 cells (right) compared to a negative control without primary antibody (left).](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74542-img0006.jpg)
![Western Blot: SREBP1 Antibody (PSH04-61) [NBP3-32977] - Western blot analysis of SREBP1 on different lysates with Rabbit anti-SREBP1 antibody (NBP3-32977) at 1/2,000 dilution. Lane 1: HeLa cell lysate Lane 2: HEK-293 cell lysate Lane 3: MCF7 cell lysate Lane 4: A549 cell lysate Lane 5: SK-Br-3 cell lysate Lysates/proteins at 20 ug/Lane. Predicted band size: 122 kDa Observed band size: 80-100 kDa Exposure time: 3 minutes; ECL; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32977) at 1/2,000 dilution was used in 5% NFDM/TBST at 4C overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1/50,000 dilution was used for 1 hour at room temperature.](http://images.novusbio.com/fullsize/nbp3-32977_rabbit-srebp1-mab-psh04-61-288202412493476.jpg "Western Blot: SREBP1 Antibody (PSH04-61) [NBP3-32977] - Western blot analysis of SREBP1 on different lysates with Rabbit anti-SREBP1 antibody (NBP3-32977) at 1/2,000 dilution. Lane 1: HeLa cell lysate Lane 2: HEK-293 cell lysate Lane 3: MCF7 cell lysate Lane 4: A549 cell lysate Lane 5: SK-Br-3 cell lysate Lysates/proteins at 20 ug/Lane. Predicted band size: 122 kDa Observed band size: 80-100 kDa Exposure time: 3 minutes; ECL; 4-20% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32977) at 1/2,000 dilution was used in 5% NFDM/TBST at 4C overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1/50,000 dilution was used for 1 hour at room temperature.")
![Immunohistochemistry: SREBP1 Antibody (PSH04-61) [NBP3-32977] - Immunohistochemical analysis of paraffin-embedded human adrenal gland tissue with Rabbit anti-SREBP1 antibody (NBP3-32977) at 1/1,000 dilution. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 2 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (NBP3-32977) at 1/1,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.](http://images.novusbio.com/fullsize/nbp3-32977_rabbit-srebp1-mab-psh04-61-2982024149263.jpg)
![Immunocytochemistry/ Immunofluorescence: SREBP1 Antibody (PSH04-61) [NBP3-32977] - Immunocytochemistry analysis of HeLa cells labeling SREBP1 with Rabbit anti-SREBP1 antibody (NBP3-32977) at 1/100 dilution. Cells were fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 5 minutes at room temperature, then blocked with 1% BSA in 10% negative goat serum for 1 hour at room temperature. Cells were then incubated with Rabbit anti-SREBP1 antibody (NBP3-32977) at 1/100 dilution in 1% BSA in PBST overnight at 4 ℃. Goat Anti-Rabbit IgG H&L (iFluor™ 488) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. Nuclear DNA was labelled in blue with DAPI. Beta tubulin (red) was stained at 1/100 dilution overnight at +4℃. Goat Anti-Mouse IgG H&L (iFluor™ 594) was used as the secondary antibody at 1/1,000 dilution.](http://images.novusbio.com/fullsize/nbp3-32977_rabbit-srebp1-mab-psh04-61-29202410484870.jpg)
![Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NBP2-76535] - Staining of human cell line A549 shows localization to cytosol. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-76535-img0001.jpg "Immunocytochemistry/Immunofluorescence: SREBP1 Antibody [NBP2-76535] - Staining of human cell line A549 shows localization to cytosol. Antibody staining is shown in green.")
![Immunohistochemistry-Paraffin: SREBP1 Antibody [NBP2-54707] - Staining of human adrenal gland shows strong cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/SREBP1-Antibody-Immunohistochemistry-Paraffin-NBP2-54707-img0001.jpg "Immunohistochemistry-Paraffin: SREBP1 Antibody [NBP2-54707] - Staining of human adrenal gland shows strong cytoplasmic positivity in glandular cells.")
![Immunohistochemistry-Paraffin: SREBP1 Antibody (SREBP1/1578) [NBP3-07878] - IHC analysis of formalin-fixed, paraffin-embedded human ovarian carcinoma. SREBP1 antibody (SREBP1/1578) at 2ug/ml. Inset: PBS instead of primary antibody; secondary only negative control.](http://images.novusbio.com/fullsize/SREBP1-Antibody-SREBP1-1578-Immunohistochemistry-Paraffin-NBP3-07878-img0001.jpg "Immunohistochemistry-Paraffin: SREBP1 Antibody (SREBP1/1578) [NBP3-07878] - IHC analysis of formalin-fixed, paraffin-embedded human ovarian carcinoma. SREBP1 antibody (SREBP1/1578) at 2ug/ml. Inset: PBS instead of primary antibody; secondary only negative control.")